ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis

Reuters Staff  |  March 25, 2016

(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis. The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said. Taltz works by blocking interleukein-17A, a…

Health Insurer Anthem Sues Express Scripts over Drug Pricing

Reuters Staff  |  March 24, 2016

(Reuters)—Health insurer Anthem Inc. said it had sued pharmacy benefit manager Express Scripts Holding Co. to recover damages from drug pricing it believes was too high. The lawsuit, filed on Monday in U.S. District Court for the Southern District of New York, is the latest development in a month’s long dispute over Anthem’s contract with…

Older Americans Taking More Medications

Andrew M. Seaman  |  March 24, 2016

(Reuters Health)—The proportion of older Americans taking at least five medications or supplements went up in a recent study. The increase in people using multiple medications paralleled an increase in the number of older Americans at risk for major drug interactions, researchers found. “That’s a concern from a public health standpoint, because it’s getting worse,”…

FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers

Reuters Staff  |  March 23, 2016

(Reuters)—The U.S. Food and Drug Administration announced on Tuesday new required class-wide safety labeling changes for immediate-release opioid pain medications. Among the changes, the FDA now requires these pain medications to carry a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. The FDA also requires several additional safety labeling…

Knowledge of Genetic Risk Doesn’t Prompt Behavior Changes

Kathryn Doyle  |  March 23, 2016

(Reuters Health)—Telling patients about their genetic risk for disease doesn’t usually lead to healthy behavior changes, such as eating better or exercising more, according to a new analysis of existing studies. Researchers selected 18 studies that tracked seven potential behavior changes—such as quitting smoking, diet, physical activity and using sun protection—among people who had received…

U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Ransdell Pierson  |  March 18, 2016

(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…

Psoriasis Drug Succeeds in Mid-Stage Study

Reuters Staff  |  March 17, 2016

(Reuters)—Drug developer Vitae Pharmaceuticals Inc. said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70% in after-hours trading. Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction…

Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants

Jessica Dye  |  March 17, 2016

NEW YORK (Reuters)—Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay a total of about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants. Following a two-month trial, jurors found that the Pinnacle hips were defectively designed, and that the…

Smartphones Not So Smart with Urgent Medical Questions

Lisa Rapaport  |  March 16, 2016

(Reuters Health)—Smartphones are the first thing many people turn to with questions about their health. But when it comes to urgent queries about issues like suicide, rape and heart attack, phones can be pretty bad at offering good medical advice, a new study suggests. Researchers tested four commonly used conversation agents that respond to users’…

Women Lag Men as Lead Authors in Top Medical Journals

Lisa Rapaport  |  March 11, 2016

(Reuters Health)—Women are more apt to be lead authors of research in major medical journals today than they were a generation ago, but they still lag significantly behind men, a recent study suggests. The gender gap matters because lead authors make key decisions on what topics to research, who to include in studies, which outcomes…

  • « Previous Page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • 71
  • …
  • 98
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences